Ramsay Hunt syndrome (VZV reactivation at geniculate ganglion) is one of the most important diagnoses not to miss in a patient presenting with facial weakness + taste loss + ear pain — because the treatment window is critical. Combined antiviral + steroid treatment initiated within 72 hours of facial palsy onset produces complete recovery in approximately 75% of cases. Treatment initiated after 72 hours produces recovery in only 30–50% of cases. The triad of ear pain + facial palsy + vesicles in the external auditory canal or on the pinna is pathognomonic — but in approximately 20% of cases the vesicles appear after the palsy (zoster sine herpete), making early diagnosis dependent on recognising the clinical pattern. Any unilateral facial palsy with ear pain and taste disturbance = Ramsay Hunt until proven otherwise, regardless of visible vesicles. The true taste vs olfaction distinction is clinically crucial — the vast majority of patients who present saying they have 'lost their sense of taste' have actually lost their sense of smell (anosmia/hyposmia). True taste (gustation) detects only five primary qualities: sweet, salty, sour, bitter, and umami. What most people experience as 'taste' (the rich flavour of coffee, strawberries, wine) is actually retronasal olfaction — aromatic volatile compounds reaching the olfactory epithelium from the back of the throat during eating. When patients say 'everything tastes the same' or 'food has no flavour,' this almost always means anosmia + intact taste. True ageusia (complete loss of gustation — cannot detect sweet, salt, sour, bitter) is much rarer and more likely to indicate a structural or neurological cause. Distinguishing these in the consultation takes 2 minutes: 'Can you taste sweetness if you put sugar on your tongue? Can you taste salt if you put salt on your tongue?' — if yes, they have anosmia not ageusia.

Understanding the physiology of flavour is essential for accurate diagnosis and patient education — if a GP tells a patient who has post-COVID anosmia that they have 'lost their sense of taste,' the patient will search for ageusia treatments, not anosmia treatments. The correct explanation is: 'You have lost your sense of smell, and because most of what we experience as taste is actually smell, your food has no flavour. But your actual taste receptors — for sweet, salt, sour, bitter — are working normally.' This explanation is accurate, helps the patient understand why antihistamines won't help, and correctly directs them toward olfactory training. The gustin (carbonic anhydrase VI) — zinc connection is mechanistically important: gustin is secreted by serous acinar cells of the parotid gland into saliva, where it acts as a trophic factor for taste receptor cell maturation and maintenance. In zinc deficiency, gustin activity falls, taste bud maintenance is impaired, and hypogeusia and dysgeusia result — even at zinc levels in the low-normal range. The clinical implication is that empirical zinc supplementation (zinc sulphate 220 mg OD × 8 weeks) is a low-risk, inexpensive therapeutic trial that is appropriate for all patients with unexplained hypogeusia/dysgeusia, particularly in those with risk factors for deficiency.

Drug-induced taste disturbance is the most commonly missed cause in primary care — over 250 drugs have taste as a listed side effect, and many are extremely common prescriptions. The key drugs to know: captopril causes taste loss in approximately 0.5% of patients (more than other ACEi — related to its sulfhydryl group which chelates zinc); terbinafine causes prolonged dysgeusia (metallic, bitter) that can persist for months after cessation (mechanism: drug concentrates in saliva and taste receptor cells, altering receptor function); clarithromycin causes a bitter metallic taste in virtually all patients at standard doses (patient education prevents early discontinuation of important antibiotic courses); metronidazole produces a well-known metallic taste that is so consistent it can be used as a compliance indicator in clinical trials. The most clinically useful approach is systematic medication review at the consultation: list every drug (including OTC) the patient takes, check each for taste-related ADRs in the BNF/electronic medicines compendium, and consider a trial withdrawal of any plausible candidate (with appropriate clinical supervision). Terbinafine-induced dysgeusia deserves special mention as it is frequently not recognised even by dermatologists who prescribe it for onychomycosis — the dysgeusia typically begins 1–3 weeks after starting treatment, is described as bitter or metallic, can be severe enough to cause weight loss and depression, and persists for 1–6 months after stopping the drug (because terbinafine concentrates in keratin-containing tissues including taste receptor cells and is released slowly). Patients starting terbinafine should be warned about this ADR.

The bedside taste test is a genuinely useful clinical skill that takes 5 minutes and immediately distinguishes true ageusia from olfactory-driven flavour loss — applying 5% sucrose solution to the anterior tongue tip and asking the patient to report the quality perceived (without swallowing) bypasses retronasal olfaction entirely and tests true taste receptor function. A patient who cannot detect concentrated sugar on their tongue has a taste receptor or CN VII problem. A patient who can detect sugar, salt, sour, and bitter normally but reports 'no taste' has anosmia. The majority of patients reporting taste loss after COVID-19 who undergo formal gustometry have normal true taste function — confirming anosmia as the actual problem. Zinc serum testing has an important caveat: serum zinc may be in the low-normal range while tissue zinc is genuinely deficient, because zinc is a positively regulated acute phase reactant — serum zinc falls during inflammation/infection and is variably reliable as a marker of zinc status. In a patient with risk factors for zinc deficiency (elderly, vegan, malabsorption, bariatric surgery, alcoholism, inflammatory bowel disease, burns, chronic diarrhoea) and unexplained dysgeusia, a therapeutic trial of zinc supplementation is reasonable even with a normal serum zinc level.

Bell's palsy with taste involvement warrants particular attention — the chorda tympani branch of CN VII carries taste from the anterior two-thirds of the tongue, and passes through the middle ear. In Bell's palsy (idiopathic facial nerve palsy, presumed HSV reactivation), the lesion is typically in the facial canal proximal to the chorda tympani takeoff, meaning taste is impaired on the ipsilateral anterior tongue. The presence or absence of taste loss in Bell's palsy helps localise the level of facial nerve injury: if taste is preserved, the lesion is distal to the chorda tympani exit; if taste is impaired, the lesion is more proximal (geniculate ganglion or above). This does not change initial management (prednisolone + aciclovir at presentation) but provides valuable prognostic information — more proximal lesions with taste involvement tend to have slower and less complete recovery. Documenting the presence or absence of taste in all Bell's palsy presentations is therefore good clinical practice. Dietitian referral for cancer-related dysgeusia (affecting 45–84% of chemotherapy patients) is an underused but evidence-based intervention — specific strategies include: using plastic cutlery (reduces metallic taste from metal-tastant interactions), serving food at cool or room temperature (reduces smell and taste distortion), marinating meat in fruit juices (masks metallic/bitter), using tart flavours (lemon, vinegar) to stimulate remaining taste receptors, and increasing protein intake via non-meat sources (dairy, eggs, legumes) for patients in whom meat is perceived as having an unpleasant taste.

Pilocarpine for xerostomia (Sjögren's syndrome or post-radiotherapy) is one of the most underused but evidence-based treatments in primary care — it is a muscarinic agonist (M3 receptor) that stimulates remaining functional salivary acinar cells to produce more saliva. In Sjögren's syndrome (where lymphocytic infiltration has destroyed approximately 50% of acinar cells by the time of diagnosis), stimulating the remaining 50% with pilocarpine produces clinically meaningful saliva production, improving both the dysgeusia and the dental caries risk associated with xerostomia. Dosing: 5 mg TDS–QDS, taken 30 minutes before meals. Side effects: sweating, flushing, increased lacrimation, urinary frequency — all dose-dependent and manageable. Contraindicated in uncontrolled asthma, acute iritis, narrow-angle glaucoma. The initiation of pilocarpine in Sjögren's is typically specialist-led (rheumatologist), but GPs can continue and dose-adjust the prescription. For post-radiotherapy xerostomia (where salivary glands have been irradiated for head/neck cancer), pilocarpine produces modest but statistically significant improvement in salivary flow and patient-reported taste and quality of life — it should be prescribed for all patients with post-radiotherapy xerostomia who do not have contraindications. The bicarbonate of soda mouthwash strategy for metallic dysgeusia is evidence-based from the oncology literature — metallic taste in chemotherapy patients is partly caused by acidic byproducts of taste receptor cell damage, and rinsing with alkaline bicarbonate solution before meals partially neutralises this, improving perceived food taste. NHS oncology departments routinely advise this for chemotherapy-associated dysgeusia. GPs can apply the same advice to drug-induced metallic dysgeusia from any cause.

The complete facial nerve recovery rate in Bell's palsy treated within 72 hours with prednisolone is approximately 70–85% — this represents a genuine treatment benefit over placebo (NNT approximately 7 for complete recovery). The addition of aciclovir to prednisolone in Bell's palsy is less clearly supported by evidence than steroids alone (the individual trials are underpowered), but the combination is recommended by NICE CKS and most neurology guidelines because the presumed viral aetiology (HSV-1 reactivation in facial canal) supports antiviral treatment, the risk is minimal, and the potential benefit in borderline cases is clinically important. For Ramsay Hunt syndrome (VZV reactivation), the evidence for combined antiviral + steroid is stronger — and the prognosis without treatment is significantly worse (only 10–20% of untreated Ramsay Hunt patients achieve complete facial recovery). The 72-hour window is critical for both conditions. Zinc supplementation for uraemic dysgeusia in dialysis patients has a specific evidence base — dialysis removes zinc in the dialysate (approximately 50–300 µg per session), leading to chronic zinc depletion in most ESRD patients on maintenance dialysis. Multiple small RCTs have shown that zinc supplementation (50 mg elemental zinc daily) improves taste acuity scores in dialysis patients within 3 months. This is one of the most evidence-based nutritional interventions in nephrology and is recommended in ESRD nutritional guidelines.

The umami receptor strategy for dysgeusia is scientifically grounded — the umami receptor (T1R1/T1R3 heterodimer, sensitive to glutamate and nucleotides) is one of the more robust taste receptor subtypes and is often partially preserved in conditions causing dysgeusia. Umami-rich foods (parmesan cheese, soy sauce, miso paste, anchovies, sun-dried tomatoes, dried mushrooms — particularly shiitake) are highly effective flavour enhancers that can make food more palatable and enjoyable even when sweet/salty/bitter perception is diminished. This strategy comes directly from the culinary medicine and oncology nutrition literature, where umami enhancement is a standard recommendation for chemotherapy-related dysgeusia. The practical advice 'add a small amount of parmesan or soy sauce to meals to boost flavour' is simple, evidence-informed, and universally applicable to patients with hypogeusia from any cause. The anticholinergic burden and xerostomia connection is particularly important in elderly patients — many older patients are prescribed multiple drugs with anticholinergic side effects (TCAs, antihistamines, bladder antimuscarinics such as oxybutynin, antipsychotics, antiemetics). The cumulative anticholinergic burden produces persistent xerostomia that impairs taste, increases dental caries risk, and worsens dysphagia. The STOPP (Screening Tool of Older People's Potentially inappropriate Prescriptions) criteria specifically identify anticholinergic polypharmacy as a prescribing concern. A medication review reducing anticholinergic burden in an elderly patient with dysgeusia + dry mouth is both a treatment for the taste disturbance and a broader improvement in prescribing quality.

The terbinafine prolonged dysgeusia follow-up point is practically important — terbinafine is lipophilic and accumulates in keratin-rich tissues (nails, skin, taste receptor cells) with a terminal tissue half-life of months. Some patients have persistent metallic/bitter dysgeusia for up to 6 months after their last terbinafine dose, and there are case reports of dysgeusia persisting for 12 months. Patients who have completed a terbinafine course for onychomycosis and then present with dysgeusia several months later may not spontaneously report or connect the drug — asking specifically about terbinafine use in the past 12 months is essential. The condition is self-limiting in the vast majority of cases, but a small number of patients have reported very prolonged dysgeusia. Zinc supplementation may accelerate recovery by replenishing the gustin-zinc system disrupted by terbinafine's zinc-chelating properties. Formal taste testing clinics: in the UK, specialist taste and smell clinics are available at a small number of academic centres (including University College London Hospital and the National Hospital for Neurology and Neurosurgery). For patients with persistent unexplained taste loss lasting more than 6 months despite thorough investigation and empirical treatment in primary care, a specialist taste clinic referral provides electrogustometry, formal threshold testing, specialist investigations, and access to clinical trials. GPs should be aware this option exists even if access is geographically limited.